Inventor seeks next big thing in cancer fight

Nov 18, 2009 By Mike Cassidy

Robert Goldman is a geek's geek, a Silicon Valley inventor who likes to know exactly how things work.

He tinkered with interactive television back in the day. More recently he developed and sold the patents to key bits of the technology that makes downloadable music possible. His sharp mind has made him rich, but even Goldman has his limits when it comes to understanding how life works.

Like when his sister was diagnosed with in 1998. How could anyone understand how that works? Goldman, who is used to finding answers, was the one left asking, Why?

"You go to the doctor and they say to you, 'You've got a 30 percent chance to live,'" says Goldman, 50. "What is this, a lottery?"

He was inspired by his sister, Amy Cohen, who was a fighter. She'd just given birth to a baby girl when she was diagnosed. She fought to be granted compassionate use of an ImClone drug awaiting federal approval. When her appeals to the company were denied, she called ImClone President Sam Waksal directly and persuaded him to give her the drug.

Her story made "60 Minutes," but her persistence did not save her life. Cohen died in 2003 at age 39.

Meantime, Goldman had started researching . What was the state of the art? What had been tried? He seized on the idea that if chemotherapy could be applied directly to tumors instead of throughout the body, some patients would have a better chance.

What he needed, he figured, was a catheter that would deliver drugs right into the supplying cancerous tumors. He pondered and tinkered and read up on medicine and devices.

"I never had any experience with medical devices," he says. "I didn't have a clue."

He started talking to doctors. The first question they'd ask, he says, was: "Where did you get your medical degree?"

"I don't have one of those," he'd reply sheepishly. Sometimes that was the end of the conversation. Then Goldman put calls in to a couple of Stanford University Medical Center doctors. They were in . Maybe they'd understand that good ideas can come from anywhere. Dr. Huy M. Do, an interventional neuroradiologist at Stanford, still remembers his initial reaction about five years ago.

"Who is this crazy guy?" Do says. But he was moved by the story of Goldman's sister and the more he listened, the more Goldman's conceptual design made sense.

"He's obviously very bright, just a great innovator," says Do, an unpaid Goldman adviser. "He's a very positive guy." Do told Goldman to keep working, concentrate on making the device smaller.

Goldman tweaked and tweaked. He formed a company, Vascular Designs, headquartered at his home. He lined up angel investors and $1.8 million in seed money. He added about $3 million of his own. He submitted his design to the Food and Drug Administration. It was rejected. Three times. Then in May, he got it: FDA approval.

"What did I do when I found out?" Goldman says. "I cried." It was a good cry.

"The fact that he was somehow able to get this through the whole FDA system that everybody complains about," says Stanford's Dr. Michael Dake, another unpaid adviser, "that's an amazing story."

It's still too early to know how widely the catheter, known as the IsoFlow, will be deployed. Every cancer case is different and Goldman's catheter is not right for all cases. Goldman's push now is to persuade doctors to try the catheter.

A Wisconsin neurologist became the first to use it recently with mixed results. The device functioned as designed, but the patient's tumor was situated in such a way that the doctor could not thread the catheter all the way to the blood vessels feeding the tumor, says Goldman, who attended the surgery.

Goldman is undeterred. He is continuing to refine the IsoFlow. There will be other cases, he says.

And if he's learned anything in the years since his sister died, it's that sometimes it takes a setback to inspire success.

(c) 2009, San Jose Mercury News (San Jose, Calif.).
Visit Mercury Center, the World Wide Web site of the Mercury News, at
Distributed by McClatchy-Tribune Information Services.

Explore further: Cancer prevention efforts in the US a mixed bag

Related Stories

A new type of spin valve that uses graphene

Jul 09, 2007

“Some people think that graphene, a form of carbon, is the material of the future,” Allen Goldman tells “It’s of high scientific interest because of its unusual electronic properties.”

Heart disease: Research off the beating patch

Jul 21, 2009

It is an amazing sight: What looks like a tiny beating heart is actually a piece of synthetic, gauze-like mesh, barely the size of a fingernail, floating in a Petri dish. And yet it keeps squeezing away, nice ...

Fingering fraud takes toll on students

Jul 31, 2006

Blowing the whistle on a professor's alleged scientific misconduct has taken a toll on the careers of six University of Wisconsin-Madison students.

Goldman Sachs, Citigroup got swine flu vaccine

Nov 05, 2009

(AP) -- Some of New York's biggest companies, including Wall Street giants Goldman Sachs and Citigroup, received doses of swine flu vaccine for at-risk employees, drawing criticism that the hard-to-find vaccine ...

Recommended for you

Cancer prevention efforts in the US a mixed bag

55 minutes ago

While there has been substantial progress in some cancer control efforts in the past several decades, like reductions in smoking and increased utilization of cancer screening, progress in some areas is lagging, according ...

Breast cancer is not one disease, experts say

Mar 30, 2015

(HealthDay)—Breast cancer isn't the same for every woman, even at the cellular level, according to a new statement from four major medical groups focused on the disease.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.